Clinical Trial Update: A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating baricitinib in pediatric patients aged 2 to under 18 with active juvenile idiopathic arthritis-associated uveitis or ANA-positive chron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ana-positive Chronic Anterior Uveitis
• Juvenile Idiopathic Arthritis-associated Uveitis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Uveitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-13